Sosei
Boehringer Ingelheim and Sosei Sign Potential $732 Million Collaboration for Schizophrenia Treatment
Boehringer Ingelheim, Sosei, Schizophrenia Treatment, Partnership, $732 Million Deal, GPR52 Targeting Portfolio
Actionable Insights Powered by AI
Boehringer Ingelheim, Sosei, Schizophrenia Treatment, Partnership, $732 Million Deal, GPR52 Targeting Portfolio